Bevacizumab is an IgG1 recombinant humanized monoclonal antibody that acts by selectively binding to circulating VEGF-A, creating a large molecule that renders it unable to bind to its cell surface receptors, reducing microvascular growth of tumor blood vessels and limiting blood supply of nutrients and oxygen to tumor tissues. The gene discussed is CD177; the disease is neoplasm.